Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Hippel James
   2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
(Last)
(First)
(Middle)
614 MCKINLEY PLACE N.E.		 3. Date of Earliest Transaction (Month/Day/Year)
08/07/2018
(Street)

MINNEAPOLIS, MN 55413		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/07/2018   M   2,398 A $ 0 5,477 D  
Common Stock 08/07/2018   F   1,094 D $ 180.14 4,382 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 08/07/2018   M     2,398   (2)   (2) Common Stock 2,398 $ 0 602 D  
Restricted Stock Units (1) 08/07/2018   D     602   (2)   (2) Common Stock 602 $ 0 0 D  
Stock Options (Right to buy) $ 108.49 08/07/2018   D     3,762   (3) 08/07/2022 Common Stock 3,762 $ 0 14,988 D  
Restricted Stock Units (1) 08/08/2018   A   3,383     (4)   (4) Common Stock 3,383 $ 0 3,383 D  
Stock Options (Right to buy) $ 177.32 08/08/2018   A   24,089     (5) 08/08/2025 Common Stock 24,089 $ 0 24,089 D  
Stock Options (Right to buy) $ 177.32 08/08/2018   A   18,066     (4) 08/08/2025 Common Stock 18,066 $ 0 18,066 D  
Restricted Stock Units (1)               (6)   (6) Common Stock 4,438   4,438 D  
Restricted Stock Units (7)               (8)   (8) Common Stock 4,925   4,925 D  
Stock Option (Right to Buy) $ 106.59               (9) 08/18/2023 Common Stock 30,400   30,400 D  
Stock Option (Right to Buy) $ 94.35               (10) 08/12/2021 Common Stock 35,000   35,000 D  
Stock Option (Right to Buy) $ 86.25               (11) 04/01/2021 Common Stock 10,000   10,000 D  
Stock Options (Right to buy) $ 125.05               (6) 08/09/2024 Common Stock 24,460   24,460 D  
Stock Options (Right to buy) $ 125.05               (12) 08/09/2024 Common Stock 32,613   32,613 D  
Stock Options (Right to buy) $ 108.49               (13) 08/07/2022 Common Stock 25,000   25,000 D  
Stock Options (Right to buy) $ 106.59               (14) 08/18/2023 Common Stock 40,533   40,533 D  
Stock Options (Right to buy) $ 86.25               (11) 04/01/2021 Common Stock 25,000   25,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Hippel James
614 MCKINLEY PLACE N.E.
MINNEAPOLIS, MN 55413		       Chief Financial Officer  

Signatures

 /s/ Brenda S. Furlow, attorney in fact for James Hippel pursuant to Power of Attorney previously filed   08/09/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) On 8/7/2018, the Board of Directors authorized discretionary vesting for 2,398 performance RSUs. The remainder of the performance RSUs were forfeited.
(3) On 8/7/2018, the Board of Directors authorized discretionary vesting for 14,988 performance options. The remainder of the performance options were forfeited.
(4) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(5) Vests 6,023 shares on 8/8/2019, 6,022 shares on each 8/8/2020, 8/8/2021, 8/8/2022
(6) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(7) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
(8) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)
(9) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) 8,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
(11) Fully exercisable
(12) Vests 8,153 shares each on 8/19/2018, 8/9/2019, 8/9/2020 and 8,154 on 8/9/2021
(13) 6,250 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
(14) Vests 10,134 shares on 8/18/17, and 10,133 shares on each of 8/18/18, 8/18/19 and 8/18/20.
 
Remarks:
Amount of Securities Beneficially Owned Following Reported Transaction was overstated by 1 share on previous filed Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.